The study has been designed to evaluate real-life drug persistence, to characterize the patient populations and drug utilization patterns associated with the use of Inflectra™, as well as its safety and effectiveness. Data generated from this study could be used to better define significant prognostic characteristics and guide short-term management and maintenance treatment decisions and to identify unmet medical needs, monitor the safety and impact of novel biosimilar medication, and direct future research.